Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Lilly’s Sofe-M shows 79% response rate in Phase 1 ovarian cancer trial, but value is long-dated.

What the company is saying

Eli Lilly is highlighting Phase 1 results for its investigational antibody-drug conjugate sofetabart mipitecan (Sofe-M) combined with bevacizumab in platinum-sensitive ovarian cancer, reporting a 79% confirmed objective response rate and 100% disease control rate. The company emphasizes that these results hold across both PARP inhibitor–treated and naïve patients, including those with typically poor outcomes. Management, including Jacob Van Naarden (EVP and President of Lilly Oncology), frames the data as evidence of a promising new treatment option, citing durable responses and a favorable safety profile. The announcement stresses that the observed efficacy exceeds historical response rates for platinum re-challenge after PARPi maintenance (41.9%), and that Sofe-M is being advanced into a global Phase 3 program (FRAmework-01) in partnership with ENGOT, GOG, and APGOT. The company also notes the selection of a lower 3 mg/kg dose for Phase 3 based on comparable efficacy and improved safety over 4 mg/kg. The tone is confident, with forward-looking statements about ongoing enrollment and the potential to address an unmet need in ovarian cancer.

What the data suggests

The Phase 1 trial enrolled 33 women with platinum-sensitive ovarian cancer, most of whom (67%) had prior PARP inhibitor exposure and 70% had prior bevacizumab. Among 29 patients with measurable disease, the confirmed objective response rate was 79.3% (23/29), including 6 complete responses (20.7%) and 17 partial responses (58.6%), with a disease control rate of 100%. Median duration of response and progression-free survival were not reached at median follow-ups of 6.2 and 10.2 months, respectively. The most common adverse events were epistaxis (73%), nausea (73%), anemia (58%), neutropenia (55%), and fatigue (52%). Grade ≥3 neutropenia occurred in 42% and anemia in 24% of patients; 3% experienced febrile neutropenia, and 9% had any-grade neuropathy (none grade ≥3). Dose reductions occurred in 42% of patients, and 6% discontinued due to adverse events. The 3 mg/kg dose chosen for Phase 3 showed similar efficacy (ORR 58.8% vs 59.0% at 4 mg/kg) but lower rates of grade ≥3 treatment-related adverse events (35.3% vs 56.4%) and dose reductions (23.5% vs 41.0%). These response rates are substantially higher than the 41.9% historical ORR for platinum re-challenge after PARPi maintenance. No financial data or commercial milestones are disclosed; the evidence is limited to clinical efficacy and safety in a small, early-phase cohort.

Analysis

The announcement presents robust Phase 1 clinical data for Sofe-M in platinum-sensitive ovarian cancer, with high response rates and detailed safety information. However, the majority of the narrative's positive tone is anchored in forward-looking statements about ongoing Phase 3 trials and the potential for future regulatory approval and patient benefit, rather than realised commercial or clinical milestones. The benefits to investors are long-term, as the next major catalyst (Phase 3 results) is at least a year away, and no immediate earnings or commercialisation impact is disclosed. The capital intensity is high, given the global, multi-part Phase 3 program, but there is no discussion of costs, revenue, or profitability. While the clinical data is strong for a Phase 1 study, the announcement does not provide sufficient evidence of near-term value creation or financial impact, and the absence of profit or cash flow metrics means the signal cannot be rated above weak_positive.

Risk flags

• ●The results are from a Phase 1 trial with only 33 patients, so efficacy and safety may not translate to larger, more diverse populations in Phase 3. Early-phase oncology trials often show higher response rates than later studies.
• ●No median duration of response or progression-free survival has been reached, so durability of benefit is unproven. Longer follow-up or larger studies may reveal less favorable outcomes.
• ●Adverse events were frequent and sometimes severe, with 42% experiencing grade ≥3 neutropenia and 24% grade ≥3 anemia, and 42% requiring dose reductions. Managing toxicity at scale could be challenging.
• ●The program is capital intensive, with a global, multi-part Phase 3 trial underway but no financial or operational cost disclosures. Delays, higher-than-expected costs, or negative trial results could materially impact value.
• ●All commercial and regulatory value is contingent on future Phase 3 success; failure to replicate Phase 1 efficacy or emergence of new safety signals would undermine the investment case.

Bottom line

Lilly’s Phase 1 data for Sofe-M in platinum-sensitive ovarian cancer show a 79% response rate and 100% disease control, far exceeding historical benchmarks for this population. The safety profile is consistent with expectations for this drug class but includes high rates of severe neutropenia and anemia, with 42% of patients requiring dose reductions. The company is advancing Sofe-M into a large, global Phase 3 program, but all value for investors depends on future results, with first registrational dosing not expected until late 2025 or early 2026. No commercial, revenue, or cost data are disclosed, and the trial’s capital requirements are likely significant. The evidence is strong for a Phase 1 study but does not guarantee Phase 3 success or regulatory approval. Investors should treat this as an early clinical signal with high upside potential but substantial execution and development risk; the next major catalyst will be Phase 3 data.

Announcement summary

(NYSE:LLY) Eli Lilly and Company announced new Phase 1 data for its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) in combination with bevacizumab, showing a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). The cORR of 79% or higher was observed in both PARP inhibitor (PARPi)-treated and PARPi-naïve patients. These results will be presented at the European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain. The Phase 1 study included a cohort of 33 women with PSOC who received Sofe-M (4 mg/kg) plus bevacizumab (15 mg/kg), with a median of three prior systemic regimens (range 1–6), including prior PARPi (67%) and prior bevacizumab (70%). As of the July 6, 2026 data cutoff, among 29 patients with measurable disease, the cORR was 79.3% (23/29; 6 complete responses [20.7%] and 17 partial responses [58.6%]), and DCR was 100%. Median duration of response (DOR) and median progression-free survival (PFS) were not reached at median follow-ups of 6.2 and 10.2 months, respectively. The most common treatment-emergent adverse events (TEAEs) were epistaxis (73%), nausea (73%), anemia (58%), neutropenia (55%), and fatigue (52%). The most common Grade ≥3 TEAEs were neutropenia (42%) and anemia (24%); febrile neutropenia occurred in 3% of patients, and any-grade neuropathy occurred in 9% of patients, with no Grade ≥3 events. Dose reductions occurred in 42% of patients, and 6% discontinued treatment due to an adverse event. The 3 mg/kg dose of Sofe-M was selected as the recommended phase 3 dose (RP3D), with ORRs of 59.0% (95% CI 42.1, 74.4) at 4 mg/kg and 58.8% (95% CI 32.9, 81.6) at 3 mg/kg; Grade ≥3 TRAEs were 56.4% at 4 mg/kg and 35.3% at 3 mg/kg, and dose reductions were 41.0% vs 23.5%. Historical real-world data for platinum re-challenge after PARPi maintenance show an ORR of 41.9%. Approximately 50% of PSOC patients have HRD-positive tumors. About 70% of ovarian cancer patients will experience recurrence. Sofe-M has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for platinum-resistant ovarian cancer (PROC) and is being evaluated in the Phase 3 FRAmework-01 program (NCT07213804), which is a global, three-part trial in partnership with ENGOT (lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT). Enrollment is ongoing globally, with first registrational dose in Q4 2025 for PROC and in Q1 2026 for PSOC. The primary endpoint of FRAmework-01 is progression-free survival (PFS), with key secondary endpoints including overall survival, objective response rate, duration of response, and safety.

Disagree with this article?